140+ investors, pharma and commercial leaders you need to know Who are some of the leading investors, pharma and commercial leaders most active this side of the Atlantic? Published by COMPANIES SUMMARISED INTRODUCTION What follows in this ebook is a summary of 140+ of the life science industry’s most notable and active venture capital, corporate venture, strategic investors, PE/crossovers, pharma companies and commercial leaders. The geography of this list is primarily UK and EU, but with several key US firms also listed. They represent $bns of combined assets under management across therapeutics, diagnostics and medtech. If you don’t already have a relationship with them, these are firms you should want to get to know. The selection represents a current snapshot of the investment, pharma firms and commercial leaders currently signed up to the 5th Annual LSX World Congress (formerly Biotech/Medtech and Money World Congress conference), taking place from 5-6 February in London 2019. In this ebook we provide a snapshot of the firms themselves, plus some key aggregated statistics of their investment and partnering preferences. COMPANIES SUMMARISED 4BIO Capital F-Prime Capital New Rhein Healthcare Investors Abingworth Forbion Capital Partners Norgine Ventures Accelerace Future Care Capital Novartis Accelmed GIMV Novo Nordisk Advent Life Sciences GL Capital Novo Seeds Aglaia Biomedical Ventures Gilde Healthcare Novo Ventures Albion Capital Global Core Medical NVM Private Equity Alsa Holdings GSK o2h Andera Partners Hadean Ventures OrbiMed Apollo Ventures HBM Partners Oxford Technology Management Areterial Capital Management Healthcap Oxon Arix Bioscience Hermes Partners Panacea Venture Arterial Capital Management High-Tech Gründerfonds Panakes Partners Asabys Ignite Capital Partners Peppermint Venture Partners Astellas Imec.Xpand Philips Health Technology Ventures AstraZeneca Industrifonden Polar Capital Bayer InHealth Ventures Questra BioCity Inkef Capital Redalpine Venture Partners BioGeneration Ventures Innogest RMI Partners Bioscience Managers Inventages Roche BioSeed Capital IP Group Rosetta Capital BlueOcean Ventures IPF Partners Ruffena Capital BNP Paribas Asset Management Ipsen Sanara Ventures Boehringer Ingelheim Jolt Capital Sanofi Bond Asian Ventures JPIF SBI JI Innovation Fund Boston Scientific Ventures Julz Co Seroba Life Sciences Breed Reply Juvenescence Seventure Bridge Valley Ventures Kissei SHS Capital Business Integration Partners Kreos Capital Siemens Healthineers Cambridge Innovation Capital Kurma Partners Simcere Pharmaceutical Group Capricorn Venture Partners LifeArc Sixth Element Capital Cascara Ventures Bvba Livanova Smith & Nephew Catapult Ventures Livzon Pharmaceutical Group Sofinnova Partners CeiRox Life Sciences Longwall Ventures SOSV Clubb Capital LSP BioVentures Spark Impact DiaMedCare M Ventures SR-One DeBere Capital Partners Medicxi Swedbank Robur Deepbridge Capital MedImmune Syncona DN Capital Medtronic Takeda Downing LLP Mercia Technologies Teva Earlybird Venture Capital Merck & Co Truffle Capital Eli Lilly MSD TusPark UK EMD Serono MTIP TVM Capital Life Science EMV Capital MVM Partners UCB Venture Enterprise Ireland NCL Technology Ventures UCL Technology Fund Epidarex Capital NeoMed UKI2S Esperante NetScientific UVM Health Network Ventures Excite Capital Partners Newable Private Investing Ventac Partners FirstMinute Capital Newstar Ventures Xeraya Capital FMC (First Momentum Ventures) New Mosaic 4BIO Capital United Kingdom 4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech - biologics, gene and cell therapy and bioinformatics. Abingworth United Kingdom For almost 30 years, Abingworth has been working alongside entrepreneurs to develop their ideas into products that have a dramatic impact on health. With a broad transatlantic approach to backing innovation, we invest in drugs, devices and diagnostics from seed-stage start-ups to publicly traded companies. By harnessing advances in life sciences, we have built a succession of companies and helped to create one of the world’s most vibrant and important industries. Abingworth has raised 11 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Clinical Co-Development Fund and Abingworth Bioventures VI, raised $105 million and £225 million ($375 million) respectively and are actively investing. Abingworth has $1.1bn under management and has invested in over 140 life science companies. Accelerace Denmark We were founded back in 2008 pioneering the accelerator space in Europe with a rebellious spirit and lofty objective: to take great technologies of tomorrow and even greater teams under our wing to make them fly. Today, this is still our mission. Building on our knowledge, we believe that talent is the key to where it all begins: Talented people with an entrepreneurial drive to challenge the status quo can be found at home, working in their sheds, labs or on their laptops. However, not all of them are visible at a glance. Our ability to spot these people and nurture their ideas and talent is the most meaningful task you can take on and we’re dedicated to that. Accelmed United Kingdom Accelmed is an investment firm focused on value creation for medical device companies and technologies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger and invests in small and mid- cap private and public companies. With its proven track record and large team of accomplished investment professionals, Accelmed’s vision is to create leading med-tech players by merging commercial platforms with small innovative growth companies, predominantly from Israel. Advent Life Sciences United Kingdom Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. We are a highly experienced team with a long- standing track record of entrepreneurial and investment success through turning break-through science into approved medicines or medical products. We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach. Our investments are focussed in new drug discovery - small molecules, biologics and new modalities med tech, enabling technologies and vaccines. As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well connected team to support each investment. We work in close alignment with our management teams, and partner with them to realise their vision - achieving superior financial returns by bringing innovation to patients. Aglaia Biomedical Ventures The Netherlands Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. We invest in novel tools and technologies as well as components of contemporary drug development. Albion Capital United Kingdom Albion Capital is a leading independent investment manager with a long-term record of backing change and growth. Combining a thematic, returns-driven investment approach with specialist expertise, we target those sectors where we see opportunities for the creation of long-term value. We are generalist investors, with areas of particular focus including healthcare and technology. Albion’s focus is on longevity as partners in order to maximise the returns for our investors and the management teams for whom we support. Within healthcare and life sciences we invest in areas including digital health, diagnostics and imaging. We also invest in commercialising IP from University College London via the UCL Technology Fund, including all aspects of life sciences from therapeutics to devices. Alsa Holdings United Kingdom ALSA Holdings is a private investment vehicle with considerable pharma, biotech and CRO strength, particularly in clinical stage development. Agnostic in terms of therapeutic area, we are principally focused on companies looking to progress to proof of concept as the next step. We are committed to working closely with management to accelerate development programs utilizing the full breadth of collective scientific and industry operational expertise to help bring new products to market. Andera Partners France Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas: Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. Apollo Ventures Germany Apollo Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer’s, Heart Disease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in